Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
260 hedge funds and large institutions have $8.33B invested in Mirati Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 70 funds opening new positions, 104 increasing their positions, 65 reducing their positions, and 45 closing their positions.
104% more call options, than puts
Call options by funds: $108M | Put options by funds: $53M
60% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 65
56% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 45
9% more funds holding
Funds holding: 238 → 260 (+22)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
13% less capital invested
Capital invested by funds: $9.58B → $8.33B (-$1.24B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$74.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$59.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.8M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$45.5M |
| 5 |
Holocene Advisors
New York
|
+$38.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$82.1M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$52.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$45.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$45.3M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$42.2M |
MRTX Hedge Fund Activity: Q4 2021 in Review
260 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2021, worth a combined $8.33B — down 13% from $9.58B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new MRTX positions and 45 closed out — a net gain of 25 holders — while 104 added to existing stakes and 65 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $74.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $82.1M sold.
- 260 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2021, up from 238 in Q3 2021.
- Funds reported $8.33B of Mirati Therapeutics, Inc. Common Stock stock for Q4 2021, down 13% quarter-over-quarter.
- 70 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2021 and 45 closed out, a net change of +25 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2021 was Point72 Asset Management, an estimated $74.5M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2021 was EcoR1 Capital, an estimated $82.1M sold.
Based on aggregated 13F filings for Q4 2021.